Inhaled Treatment for Chronic Obstructive Pulmonary Disease: What's New and How Does It Fit?

QJM. 2016 Aug;109(8):505-12. doi: 10.1093/qjmed/hcv212. Epub 2015 Nov 11.

Abstract

Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled drugs and inhaler devices have recently been licensed and approved for prescribing to patients with COPD; many such drugs have been formulated in devices to deliver two different drugs at the same time. The evidence based review article highlights all of the drugs now licensed, describes some of the evidence surrounding their use and highlights practical steps in helping decide when these drugs should be considered in the context of guidelines.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use*
  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Bronchodilator Agents / therapeutic use*
  • Delayed-Action Preparations
  • Drug Combinations
  • Drug Prescriptions
  • Humans
  • Muscarinic Antagonists / therapeutic use*
  • Osteoporosis / chemically induced
  • Pneumonia / chemically induced
  • Practice Guidelines as Topic
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Delayed-Action Preparations
  • Drug Combinations
  • Muscarinic Antagonists